Graft-versus-host disease following interferon therapy for relapsed chronic myeloid leukaemia post-allogeneic bone marrow transplantation.
The combination of donor leucocytes, with or without interferon, has produced encouraging responses in patients with haematological relapse following allogeneic BMT for chronic myeloid leukaemia (CML). A 25-year-old male received low-dose interferon-alpha alone for haematological relapse occurring 10 months following an allogeneic BMT for Ph-positive CML. Interferon therapy was complicated by severe GVHD requiring immunosuppressive therapy. The patient was subsequently found to be in complete haematological and cytogenetic remission, raising the possibility of an immune-mediated antileukaemic action.
Browett
P J
PJ
Department of Molecular Medicine, University of Auckland School of Medicine, New Zealand.
Nelson
J
J
Tiwari
S
S
Van de Water
N S
NS
May
S
S
Palmer
S J
SJ
D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D006086:Graft vs Host Disease / Q000209:etiology*; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D008297:Male; D011994:Recombinant Proteins; D014184:Transplantation, Homologous
D007370:Interferon Type I; D011994:Recombinant Proteins